Laghu Udyog Bharati (LUB) proudly represented the voice of India’s MSME pharmaceutical sector at a high-level policy consultation meeting convened by Hon’ble Dr. V.K. Paul and his team at NITI Aayog, focused on framing the Pharmaceutical Policy for 2030.
LUB’s delegation, comprising Dr. Rajesh Gupta, Shri Sanjay Singla, and Shri Nipun Jain, highlighted ground-level challenges faced by MSMEs and presented pragmatic policy recommendations.
A key point raised was the difference between NSQ (Not of Standard Quality) and SQ (Substandard Quality) drugs. The team emphasized that over 97% of MSME-manufactured drugs comply with quality standards, despite negative portrayals in the media. They proposed a Standard Quality Drug Declaration, and demanded equitable regulatory scrutiny for large corporates with high recall rates.
In support of small-scale pharma units, LUB urged the extension and simplification of Revised Schedule M for companies with turnovers below ₹50 crores. They recommended performance-based incentives ranging from ₹50 lakhs to ₹2 crores post joint CDSCO-State inspections and successful license issuance.
To bridge the manpower and skill gap, the delegation advocated for a reform in pharmacy education, suggesting a 3-year academic + 2-year articleship structure similar to the CA model, and introducing Industry 4.0 and AI-focused skilling programs.
Addressing global trade bottlenecks, LUB requested the removal of unnecessary export NOCs, arguing that importing countries should bear evaluation responsibility, aligning India with international best practices.
Dr. V.K. Paul assured the delegation that these concerns would be taken seriously and welcomed further interactions with LUB to understand the MSME pharma landscape more deeply.
LUB’s physical presence ensured that the voice of India’s MSME pharma sector was heard clearly and powerfully at the national policy table.
